It looked at differences between patients given a Moderna booster after having had two jabs of the Pfizer vaccine and those who received the Pfizer vaccine three times. While about 70 percent of ...

Moderna chief executive Stephane Bancel said in an interview the company aimed to have a booster ready by August 2022, before next autumn when he said more vulnerable people may need it.

There's one big difference though - Pfizer is seeking a green light for second booster dose of Comirnaty for people aged 60 and over and those in high-risk groups, while Moderna is going for a ...

Health officials say eligible residents can receive the COVID-19 vaccine at the same time as or at any time before or after ...

Moderna's chief executive. He stressed however that the mRNA-1273.214 candidate – which combines the current SpikeVax booster with an Omicron-specific candidate – is the company's lead ...

The COV-Boost study was cited by British officials when they announced that Pfizer and Moderna were preferred for use in the country's booster campaign, but the data has only been made publicly ...

Moderna said it is suing Pfizer and its German partner BioNTech for patent infringement linked to the development of the first Covid-19 vaccines. The US biotech company is alleging that mRNA ...

Please confirm that you would like to log out of Medscape. If you log out, you will be required to enter your username and password the next time you visit. Log out ...

Heading into Moderna’s (Nasdaq ... lost out on a few different things here and it’s very much become a show-me story for how well can they contract. How competitive are they going to be ...

Moderna, Inc. engages in the development of transformative medicines based on messenger ribonucleic acid (mRNA). Its product pipeline includes the following modalities: prophylactic vaccines ...

Miller comments, “There's no greater synergy for me than to bring myself to Moderna.” Moderna is a Cambridge, MA based biotech company that made a name for itself in 2020 upon releasing one of ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...